close
Add to watchlist
BioMimetic Therapeutics Inc (BMTI) Healthcare
BioMimetic Therapeutics, Inc. develops and commercializes regenerative protein therapeutic-device combination products. Its products are primarily used for bone and tissue regeneration for the repair and healing of musculoskeletal injuries and conditions affecting bones, tendons, ligaments, and cartilage within orthopedic, spine, and sports injury applications. The company's lead orthopedic product candidate includes Augment Bone Graft, for treating bone defects and injuries. It also has pre-clinical products, which include Augment Injectable Bone Graft for closed non-surgical fracture treatment; TBD for spine fusion; and Augment C for cartilage repair and Augment LT for ligament and tendon repair. The company was formerly known as BioMimetic Pharmaceuticals, Inc. and changed its name to BioMimetic Therapeutics, Inc. in July 2005. BioMimetic Therapeutics, Inc. was founded in 1999 and is headquartered in Franklin, Tennessee.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 2.09 |
| Volume | 430543 |
| Volume Avg | 274662 |
| 52 Week High | 14.49 |
| 52 Week Low | 1.87 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -1.19 |
| EPS change Q/Q | -22.22% |
| EPS change Q/Q Yr ago | -28.21% |
| EPS change Q/Q next Q est | -47.37% |
| EPS change Y/Y | -20.31% |
| REV change Q/Q | 0% |
| REV change Q/Q Yr ago | 0% |
| EPS next Q est | -0.19 |
| EPS next Y est | -0.80 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |